Synta (SNTA) Launches HDC Platform (StreetInsider.com)
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the launch of its Hsp90-inhibitor Drug Conjugate (HDC) platform, which leverages the Company’s expertise in chaperone biology and medicinal chemistry to create a new class of anti-cancer therapies. Current oncology therapeutics generally fall into two categories: cytotoxic agents and molecularly targeted therapies. Cytotoxic agents are often broadly active, but have the disadvantage of high toxicity caused by damage to normal cells, which limits their utility.
What Is Inovio Worth After The Roche Deal? (Seeking Alpha)
Inovio Pharmaceuticals Inc (NYSEMKT:INO) just closed a $422 million deal with Roche Pharmaceuticals changing the whole perception of the company and its technology. The deal covers only two of Inovio’s current pipeline of nine drugs. The drugs included in the partnership agreement are INO-5150 for prostate cancer, and INO-1800 for Hepatitis B. This deal fundamentally revalues Inovio. One of the largest pharmaceutical companies in the world feels that Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s DNA vaccine technology, and electroporation technology is worth investing over 400 million dollars in.
Alnylam Pharmaceuticals Management Presents at Morgan Stanley Healthcare Conference (Transcript) (Seeking Alpha)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Morgan Stanley Healthcare Conference Call September 10, 2013 11:00 AM ET [No presentation session for this event.]
Top Stocks: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Penn Virginia Corporation (NYSE:PVA), Walter Energy, Inc. (NYSE:WLT), Fusion-IO, Inc.(NYSE:FIO) (TechSonian)
Value Penny Stocks issues a special report on Inovio Pharmaceuticals Inc (NYSEMKT:INO), Penn Virginia Corporation, Walter Energy, Inc., Fusion-IO, Inc.. Inovio Pharmaceuticals Inc shares increased 14.86% to $2.55. Roche and Inovio Pharmaceuticals, Inc. on Sept. 10 announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.